French biotech Brenus Pharma has raised an €11 million Series A extension to complete the Phase 1 development of its lead colorectal cancer immunotherapy and advance a second programme from its platform.
The COVID-19 pandemic transformed RNA technologies into one of the most visible scientific breakthroughs of the decade. mRNA vaccines demonstrated unprecedented speed of development, large-scale manufacturing capability and global deployment, pushing RNA therapeutics into the public spotlight. But according to companies working in the field, the pandemic was not the beginning of the RNA story. Instead, it accelerated technologies that had already been under development for years.
Belgian techbio Sightera Biosciences has raised €3 million in pre-seed financing to expand its AI drug discovery platform and advance a pipeline of small molecules in oncology and fibrosis.
GSK has stopped developing camlipixant for refractory chronic cough after mixed Phase 3 results, adding another setback to a P2X3 drug class that has repeatedly struggled to turn biological promise into convincing clinical benefits.
Biotech AustriaOn 13–14 October 2026, BIOTECH SUMMIT AUSTRIA brings Europe’s biotech community to Innsbruck for high-level keynotes, policy insights, partnering and networking
in a landmark Alpine setting.
UK biotech companies raised £2.11 billion in equity financing in the second quarter of 2026, as a record round for Isomorphic Labs pushed venture investment to its highest level in five years.
French techbio Orakl Oncology has secured exclusive rights to four undisclosed oncology assets from Sanofi, giving the startup an opportunity to test whether its combination of patient-derived tumour models and artificial intelligence can improve drug development decisions.
UK biotech Mission Therapeutics has sold its Phase 2-ready acute kidney injury drug MTX652 to Australia’s Dimerix in a deal worth up to $292 million (€254.7 million), freeing Mission to concentrate resources on its central nervous system (CNS) pipeline.
Eli Lilly has agreed to acquire AtaiBeckley for up to $3.8 billion (€3.3 billion), turning a psychedelic drug developer built from German and British roots into one of the sector’s largest pharmaceutical takeovers.
Sanofi has sued Pfizer and Moderna, alleging that their COVID-19 and respiratory syncytial virus (RSV) vaccines infringe patents covering the delivery of messenger RNA using lipid nanoparticles it acquired through the acquisition of Translate Bio in 2021.